Gharaghani Maral, Hivary Sahar, Taghipour Simin, Zarei-Mahmoudabadi Ali
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Med Microbiol Immunol. 2020 Oct;209(5):603-612. doi: 10.1007/s00430-020-00672-4. Epub 2020 Apr 6.
Luliconazole is a new antifungal that was primarily used for the treatment of dermatophytosis. However, some studies have shown that it has excellent efficacy against Aspergillus and Candida species in vitro. The present study aimed to evaluate of luliconazole activity against some Fusarium species complex isolates. In this study, 47 isolates of Fusarium were tested against several antifungals including luliconazole. All species were identified using morphology features, and PCR sequencing and antifungal susceptibility were performed according to CLSIM38 A3 guideline. Our results revealed that luliconazole has a very low minimum inhibitory concentration value (0.0078-1 µg/ml) in comparison with other tested antifungals. Amphotericin B had a poor effect with a high MIC (64 µg/ml), followed by terbinafine (32 µg/ml), posaconazole (16 µg/ml), caspofungin (16 µg/ml), voriconazole (4 µg/ml), and itraconazole (4 µg/ml). Overall, our findings indicated that luliconazole has great activity against environmental and clinical Fusarium species complexes in comparison to tested antifungals.
卢立康唑是一种新型抗真菌药，主要用于治疗皮肤癣菌病。然而，一些研究表明，它在体外对曲霉菌和念珠菌具有优异的疗效。本研究旨在评估卢立康唑对一些镰刀菌复合种分离株的活性。在本研究中，对47株镰刀菌进行了包括卢立康唑在内的几种抗真菌药的测试。所有菌种均通过形态学特征进行鉴定，并根据CLSIM38 A3指南进行PCR测序和抗真菌药敏试验。我们的结果显示，与其他测试的抗真菌药相比，卢立康唑的最低抑菌浓度值非常低（0.0078 - 1μg/ml）。两性霉素B效果不佳，MIC较高（64μg/ml），其次是特比萘芬（32μg/ml）、泊沙康唑（16μg/ml）、卡泊芬净（16μg/ml）、伏立康唑（4μg/ml）和伊曲康唑（
